Raghunandan Sharmila, Josephson Cassandra D, Verkerke Hans, Linam W Matthew, Ingram Treva C, Zerra Patricia E, Arthur Connie M, Stowell Sean R, Briones Michael, Chonat Satheesh
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Aflac Cancer and Blood Disorders Center, Atlanta, GA, United States.
Front Pediatr. 2020 Dec 29;8:616731. doi: 10.3389/fped.2020.616731. eCollection 2020.
Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.
大多数新冠病毒病患儿无症状或症状轻微。那些病情危重的患儿会出现急性呼吸窘迫综合征（ARDS）和急性肾损伤（AKI）。肺功能的迅速恶化与新冠病毒病成年患者肺部出现的微血管病变和免疫介导过程有关。补体介导的急性肺损伤的作用得到了严重急性呼吸综合征冠状病毒（SARS-CoV）动物模型、对死于新冠病毒病患者的肺组织评估以及新冠病毒病ARDS对补体抑制的反应的支持。我们总结了一名接受恢复期血浆和依库珠单抗治疗的新冠病毒病患儿的情况，并对炎症途径进行了详细评估。
